Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells

Cancer Letters

Volumn 298, Issue 2, 2010, Pages 212-221

  Ahn, Quein ^a   Jeong, Soo Jin ^a   Lee, Hyo Jung ^a   Kwon, Hee Young ^a   Han, Ihn ^a   Kim, Hyun Seok ^b   Lee, Hyo Jeong ^a   Lee, Eun Ok ^a   Ahn, Kwang Seok ^a   Jung, Min Hyung ^c   Zhu, Shudong ^d   Chen, Chang Yan ^d   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; COX 2; Decursin; KBM 5; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 2; DECURSIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

APOPTOSIS; BENZOPYRANS; BLOTTING, WESTERN; BUTYRIC ACIDS; CASPASE 3; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; IN SITU NICK-END LABELING; LEUKEMIA, MYELOID; LYMPHOCYTES; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR STRUCTURE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE C; SIGNAL TRANSDUCTION; U937 CELLS;

EID: 77957933561     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.07.007     Document Type: Article

References (34)

1. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann. Int. Med. 1999, 131:207-219.
2. Bedi A., Zehnbauer B.A., Barber J.P., Sharkis S.J., Jones R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994, 83:2038-2044.
3. Kim H.S., Chi H.J. Studies on the components of Umbelliferae plants in Korea: pharmacological study of decursin, decursinol and nodakenin. Korean J. Pharmacog. 1970, 25-32.
4. Konoshima M., Chi H.J., Hata K. Coumarins from the root of Angelica gigas Nakai. Chem. Pharm. Bull (Tokyo) 1968, 16:1139-1140.
5. Ahn K.S., Sim W.S., Kim I.H. Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Planta Med. 1996, 62:7-9.
6. Jiang C., Guo J., Wang Z., Xiao B., Lee H.J., Lee E.O., et al. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. Breast Cancer Res. 2007, 9:R77.
7. Kim H.H., Sik Bang S., Seok Choi J., Han H., Kim I.H. Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells. Cancer Lett. 2005, 223:191-201.
8. Lee S., Lee Y.S., Jung S.H., Shin K.H., Kim B.K., Kang S.S. Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch. Pharm. Res. 2003, 26:727-730.
9. Singh R.P., Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer 2006, 13:751-778.
10. Jiang C., Lee H.J., Li G.X., Guo J., Malewicz B., Zhao Y., et al. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res. 2006, 66:453-463.
11. Kim H.H., Ahn K.S., Han H., Choung S.Y., Choi S.Y., Kim I.H. Decursin and PDBu: two PKC activators distinctively acting in the megakaryocytic differentiation of K562 human erythroleukemia cells. Leukemia Res. 2005, 29:1407-1413.
12. Wang Z.B., Liu Y.Q., Cui Y.F. Pathways to caspase activation. Cell Biol. Int. 2005, 29:489-496.
13. Romagnoli M., Seveno C., Bataille R., Barille-Nion S. Survivin in cancerology: molecular aspects and therapeutic applications. Med. Sci. (Paris) 2008, 24:821-827.
14. Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., Shiraishi F., Taba Y., Miwa Y., et al. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem. Pharmacol. 2007, 73:1318-1329.
15. Younis T., Hache K.D., Rayson D., Dewar R., Gray S., Barnes P.J. Survivin and COX-2 expression in male breast carcinoma. Breast 2009, 18:228-232.
16. Krysan K., Dalwadi H., Sharma S., Pold M., Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res. 2004, 64:6359-6362.
17. Maxia C., Perra M.T., Demurtas P., Minerba L., Murtas D., Piras F., et al. Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium. Mol. Vis. 2009, 15:458-463.
18. Yim D., Singh R.P., Agarwal C., Lee S., Chi H., Agarwal R. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005, 65:1035-1044.
19. Salvesen S.G., Stennicke H.R. Properties of the caspases. Biochim. Biophys. Acta 1998, 1387:17-31.
20. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
21. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
22. Zamzami N., Brenner C., Marzo I., Susin S.A., Kroemer G. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 1998, 16:2265-2282.
23. Richter B.W., Duckett C.S. The IAP proteins: caspase inhibitors and beyond. Sci. STKE 2000, 2000:PE1.
24. Yang Y.L., Li X.M. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res. 2000, 10:169-177.
25. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14:5000-5005.
26. Capalbo G., Rodel C., Stauber R.H., Knauer S.K., Bache M., Kappler M., et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther. Onkol. 2007, 183:593-599.
27. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. Exp. Opin. Ther. Targets 2008, 12:463-476.
28. Carter B.Z., Mak D.H., Schober W.D., Cabreira-Hansen M., Beran M., McQueen T., et al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006, 107:1555-1563.
29. Erkanli S., Bolat F., Kayaselcuk F., Demirhan B., Kuscu E. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol. Oncol. 2007, 104:320-325.
30. Bakhle Y.S. COX-2 and cancer: a new approach to an old problem. Br. J. Pharmacol. 2001, 134:1137-1150.
31. Bobadilla R.V., Barnett E.M., Randels C.L. COX-2 inhibitors and the heart: putting risk in perspective. Adv. Nurse Pract. 2005, 13:48-50.
32. Rajakariar R., Yaqoob M.M., Gilroy D.W. COX-2 in inflammation and resolution. Mol. Interv. 2006, 6:199-207.
33. Teran-Estrada L., Miranda-Limon J.M., Galvan-Villegas F. Cardiovascular risk of cyclooxygenase selective inhibitors. Rev. Med. Inst. Mex. Seguro. Soc. 2008, 46:287-299.
34. Falandry C., Canney P.A., Freyer G., Dirix L.Y. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann. Oncol. 2009, 20:615-620.